Patent Enhances and Broadens the Company’s Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric ...

Paramedic Alison Tarrant had struggled with binge-eating and her weight after having children and, in 2019 after reaching 16 ...

A top surgeon is being sued for more than £200,000 after a mother-of-three ended up hospitalised with malnutrition when a ...

Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and HypoglycemiaIRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ...

Gastric Balloon System and the DBSN™ system (but excluding cash). Therefore, at the closing of the transactions contemplated by the asset purchase agreement, the Obalon ...

Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat obesity, in the country. Last summer, the company withdrew the Allurion ...

Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves muscle mass in patients. The company noted ...

Allurion's flagship offering, the Allurion Program, integrates the Allurion Gastric Balloon, a swallowable device that aids in weight loss without the need for a surgical procedure. The program ...

The open-label, multicenter, randomized AUDACITY trial (ClinicalTrials.gov Identifier: NCT05368259) evaluated the safety and efficacy of the Allurion Gastric Balloon in adults aged 22 to 65 years ...

ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on July 8, 2025 ...